U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. K S Choi Corp - 07/13/2017
  1. Warning Letters

CLOSEOUT LETTER

K S Choi Corp


Recipient:
K S Choi Corp

United States

Issuing Office:

United States


 

  

Black HHS-Blue FDA Logo

 

 

 
Los Angeles District
19701 Fairchild Road
Los Angeles, CA 92612 

VIA UNITED PARCEL SERVICE
SIGNATURE REQUIRED

July 13, 2017

Mr. Kak Soo Choi, Chief Executive Officer/Owner
K.S. Choi Corp
179 W. 39th St.
Los Angeles, CA 90037

Dear Mr. Choi:
The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter (WL #40-13), dated 05/17/13. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Kelly D. Sheppard
Director, Compliance Branch
Division 3/West
Office of Medical Device and Radiological Health Operations
 

Back to Top